Literature DB >> 1775158

Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

M J Blackman1, I T Ling, S C Nicholls, A A Holder.   

Abstract

The amino-terminal sequence has been obtained for 2 fragments of the Plasmodium falciparum T9/94 merozoite surface protein precursor (PfMSP1) and these have been compared with the sequence predicted from the gene. These data define the position of these fragments in the precursor and indicate that the C-terminal sequence which is carried into the red cell during invasion consists of 2 epidermal growth factor (EGF)-like domains. A homologous cleavage sequence and domain structure can be identified in the MSP1 molecules of other malarial species. In addition the results suggest that the smaller fragment is not N-glycosylated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1775158     DOI: 10.1016/0166-6851(91)90127-r

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  85 in total

1.  Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum.

Authors:  L Wang; C G Black; V M Marshall; R L Coppel
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

3.  Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys.

Authors:  Sheetij Dutta; Deep C Kaushal; Lisa A Ware; Sunil K Puri; Nuzhat A Kaushal; Atul Narula; D S Upadhyaya; David E Lanar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Authors:  Zhi-Hong Zhang; Pei-Hong Jiang; Ning-Jun Li; Mi Shi; Weida Huang
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

5.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

6.  Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1.

Authors:  Y P Shi; U Sayed; S H Qari; J M Roberts; V Udhayakumar; A J Oloo; W A Hawley; D C Kaslow; B L Nahlen; A A Lal
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

7.  Characterisation of PfRON6, a Plasmodium falciparum rhoptry neck protein with a novel cysteine-rich domain.

Authors:  Nicholas I Proellocks; Lev M Kats; David A Sheffield; Eric Hanssen; Casilda G Black; Karena L Waller; Ross L Coppel
Journal:  Int J Parasitol       Date:  2008-11-27       Impact factor: 3.981

8.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

9.  IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil.

Authors:  Cristiane G Morais; Irene S Soares; Luzia H Carvalho; Cor Jesus F Fontes; Antoniana U Krettli; Erika Martins Braga
Journal:  Parasitol Res       Date:  2005-03-10       Impact factor: 2.289

Review 10.  Potential immune mechanisms associated with anemia in Plasmodium vivax malaria: a puzzling question.

Authors:  Thiago Castro-Gomes; Luiza C Mourão; Gisely C Melo; Wuelton M Monteiro; Marcus V G Lacerda; Érika M Braga
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.